A handheld scanning probe based on broadband Diffuse Optical Spectroscopy (DOS) was used in combination with dynamic contrast enhanced MRI (DCE-MRI) to quantitatively characterize locally-advanced breast cancers in six patients. Measurements were performed sequentially using external fiducial markers for co-registration. Tumor patterns were categorized according to MRI morphological data, and 3D DCE-MRI slices were converted into a volumetric matrix with isotropic voxels to generate views that coincided with the DOS scanning plane. Tumor volume and depth at each DOS measurement site were determined, and a tissue optical index (TOI) that reflects both angiogenic and stromal characteristics was derived from broadband DOS data.
Introduction
Magnetic Resonance Imaging (MRI) is expected to have an important role as an adjunct to mammography and ultrasound in the diagnosis and management of breast cancer (1-3). Dynamic contrast enhanced MRI (DCE-MRI) can provide high-resolution images of both structural and functional parameters related to perfusion and permeability of the tumor capillary network by the characteristics of exogenous contrast-agent dynamics (4). These data are correlated with tumor neoangiogenesis and can be used to distinguish between malignant and benign tissues, as well as provide fundamental information on tumor biology (5, 6) .
MRI can be performed in patients with dense breast tissue with greater sensitivity than mammography. In addition, it provides a three dimensional image, and the procedure does not involve ionizing radiation. But MRI also has several disadvantages such as the high cost per test, variability in performance due to lack of standardized imaging protocols, and wide variations in the reported specificity (30% to 80%) (7) (8) (9) . Some benign tissues such as fibroadenoma or fibrocystic changes also show strong contrast enhancements, and may demonstrate contrast agent kinetics similar to malignant tumors. There is a growing concern that MRI may lead to more aggressive treatments for breast cancer without improving patient outcome.
A possible solution for improving the specificity of breast MRI involves combining the functional capabilities of Diffuse Optical Spectroscopy (DOS) with DCE-MRI to better characterize tumors found in human breast tissue. DOS is a non-invasive optical technique that employs nearinfrared (NIR) light to characterize the optical properties of thick tissues quantitatively. Although NIR methods were first applied to breast diaphanography nearly 80 years ago, quantitative DOS methods employing time-or frequencydomain photon migration technologies have only recently been used for breast imaging. DOS combines experimental measurements and model-based data analysis to measure the bulk absorption and reduced scattering properties of highly scattering media. NIR light (600 nm to 1000 nm) propagation in tissue is dominated by scattering (10). Diffusive photons probe a large sample volume, providing macroscopically averaged absorption and scattering properties at depths up to a several centimeters.
Within the NIR spectral region, the dominant molecular absorbers in tissue are oxygenated hemoglobin (Hb-O 2 ) and reduced hemoglobin (Hb-R), water, and lipid (11) (12) (13) . Tissue scattering properties are believed to depend upon intracellular structures such as nuclei (14, 15) and mitochondria (16) , and extra-cellular components such as collagen (17). DOS characterizes tissue by functional rather than exclusively structural criteria and has been shown to have sensitivity to tumor angiogenesis, edema, and hypoxia in pilot clinical trials (17-21).
Coregistration is one major component of any effort to combine MRI and DOS. Our past efforts have progressed from animal models to phantoms, to human subjects. We first performed qualitative coregistration in a rat tumor model (22) . MRI and DOS were used to classify tumors as viable, necrotic, and edematous from measures of T2 relaxation, enhancement, hemoglobin oxygenation saturation (S T O 2 ), and water concentration. We have further demonstrated that MRI and DOS measurements in emulsion phantoms produced highly correlated quantitative measures of lipid and water concen-trations (23). DOS and contrast-enhanced MRI measures of a tumor at two time points during a neoadjuvant chemotherapy treatment demonstrated similar measures of tumor spatial and functional characteristics (24). Other groups have sought to coregister information in different capacities between MRI and DOS (21, [25] [26] [27] [28] [29] [30] .
In this pilot study, we build upon previous work to study the comparison of tumor contrast observed by MRI and DOS in human subjects. Previously, we compared DCE-MRI and DOS measurements of a tumor treated with neoadjuvant chemotherapy in a single human subject (24). The comparison between methods is now extended to six subjects with confirmed breast cancers. Our goal is to understand the similarity and differences between tumor contrast viewed by DCE-MRI and DOS, and how these insights can be incorporated into future studies.
Materials and Methods

Subjects
Six patients with breast cancer confirmed by biopsy or fine needle aspiration were studied. The patient age ranged from 31 to 56 (mean 44 ± 9). The average patient body mass index (BMI) was 31.0 ± 3.2 kg m -2 with a range of 25.8 to 34.2. All patients provided informed written consent for DOS and MRI studies. Both studies were approved by the Institutional Internal Review Board. Table I summarizes the patient characteristics and clinical findings.
DOS Instrumentation and Measurements
Broadband DOS measurements were made with the Laser Breast Scanner (LBS, Fig. 1a ). The LBS is a bedside-capable system that combines frequency-domain photon migration (FDPM) with steady-state (SS) tissue spectroscopy to measure complete (broadband) NIR absorption and reduced scattering spectra of breast tissue in vivo. Detailed descriptions of the instrumentation and theory have been provided elsewhere (31) but the salient features are reported here. The FDPM component uses six fiber-coupled laser diodes (658, 682, 785, 810, 830 , and 850 nm) intensity modulated from 50 to 600 MHz in 401 steps using the swept RF output of a Network Analyzer. An avalanche photodiode (APD) in contact with the tissue detects the diffusely reflected light and transmits these signals to the Network Analyzer phase sensitive detector. The frequency-dependent phase and amplitude of the optical signals are fit to a diffusive model of light transport to determine the tissue absorption and reduced scattering coefficients. The FDPM signals were calibrated using a tissue phantom with known optical properties.
The steady-state component of the LBS consists of a highintensity tungsten-halogen source and a spectrometer. Diffuse reflectance spectra are measured between 650 and 1000 nm using a 1 mm fiber coupled to a cooled 16 bit CCD imaging spectrometer (Oriel Inc.). Non-invasive tissue measurements are made using a hand-held probe equipped with an FDPM laser fiber bundle, APD, and SS source and detector fibers (Fig. 1b) . The source and detector separation was 28 mm. The average laser optical power launched into the tissue is about 10-20 mW (maximum 16 W/cm 2 from a 400 micron diameter fiber). The total measurement time to generate complete NIR absorption and scattering spectra from a single position is typically about 30-45 seconds (with the laser active for less than six seconds).
The FDPM and SS information are used together in order to produce complete absorption and reduced scattering spectra across the NIR. A power-law fit to the six FDPM reduced scattering values predicts the reduced scattering at all NIR wavelengths. After correcting for scattering using this power-law fit, we then determine the absolute SS diffuse reflectance scale by scaling the SS spectra to the FDPM absorption values. The resulting corrected SS spectra are then fit to a diffusive model to determine the complete NIR absorption spectrum. From the absorption spectrum quantitative concentration measurements of oxygenated hemoglo-bin (Hb-R), deoxygenated hemoglobin (Hb-O 2 ), water, and lipid are calculated. The exact algorithm has been discussed in detail elsewhere (32). From these parameters total hemoglobin concentration [(THC) = (Hb-R) + (Hb-O 2 )] and tissue hemoglobin oxygenation saturation [S t O 2 = (Hb-O 2 )/(THC)] × 100%) are calculated. A contrast function was used to combine DOS measurements to locate the location of maximum tumor optical contrast: Tissue Optical Index, TOI = (Hb-R)(H 2 O)/(Lipid). The parameters of this contrast function were determined from an evaluation of DOS measurements in a population of 58 malignant breast tumors. Data were analyzed with custom software developed in Matlab (version 6.0.0.88, The MathWorks, Inc). DOS measurements were made by placing the hand-held probe on the tissue surface with light pressure to ensure contact of the optical fibers. DOS measurements were made by moving the handheld probe to discrete locations along a line at 1.0 cm intervals to form a linescan across the tumor and surrounding normal tissue. The number of DOS positions varied depending on the tumor size. For comparison, a linescan was performed at an identical location on the contralateral breast (Fig. 1c ). Two measurements were made in each location to test accuracy and all measurement positions were marked on the skin with a surgical pen. The approximate time for a complete DOS study including calibration time is 30-45 minutes.
MRI-DOS Coregistration
The MRI study was performed following the DOS study on the same day. The two modalities were coregistered with aid of adhesive disk-shaped multi-modality imaging markers (IZI Medical, Baltimore, MD) that appear bright on T1weighted MR images. After the DOS measurements were performed, the imaging markers were placed on the breast in odd numbered line-scan sites of the DOS measurements at 2.0 cm intervals, i.e., for a 9 cm line-scan fiducial markers are placed on linescan sites 1, 3, 5, 7, and 9 (the markers are 1.4 cm in diameter and thus could not be placed on each DOS measurement site). The marker has a hollow center which can be aligned accurately with the penmarked position for DOS study. The patient then went directly to the MRI facility.
MRI Instrumentation and Measurements
The MRI study was performed using a 1.5 T Phillips Eclipse MR scanner with a dedicated breast coil. The patient was placed into the scanner in a prone position. After the localizer scan, sagittal view T1-weighted pre-contrast images were acquired from the breast of concern, using a spin echo pulse sequence with TR = 1000 ms, TE = 12 ms, FOV = 22 cm, matrix size = 256 × 256, and 34 slices with 3 or 3.5 mm thickness. Following this, a T1-weighted 3D SPGR (RF-FAST) pulse sequence with 16 frames (repetitions) was prescribed for dynamic imaging. Thirty-two axial slices with 4 mm thickness without gap were used to cover bilateral breasts. The imaging parameters were TR = 10 ms, TE = 3.6 ms, flip angle = 20°, acquisition-matrix size = 256 × 128, and FOV varying between 32 and 38 cm. The scan time was 42 sec per acquisition. The sequence was repeated 16 times for dynamic acquisitions, four pre-contrast, and 12 post-contrast sets. The contrast agent (Omniscan®, 1 cc/10 lbs body weight) was manually injected at the beginning of the 5 th acquisition, and was timed to finish in 12 seconds to make the bolus length consistent for all patients. Immediately following the contrast, 10 cc saline was used to flush the contrast medium. After all 16 frames were acquired, the post-contrast enhancement maps at different times after injection can be obtained by subtracting the mean pre-contrast images (averaged over frames 1-4) from post-contrast enhanced images at a different time. Since the early enhancement maps best differentiate malignant from benign tissues, in this study enhancement maps obtained from the 6 th frame (i.e., at 1 min after contrast injection) were used in the analysis. Figure 2a shows several Sagittal view pre-contrast T1weighted images, on which the five fiducial markers can be clearly seen. Fiducial markers #1-5 are labeled from lateral to medial right breast. The coverage for the bilateral axial view dynamic contrast enhanced study was prescribed based on these Sagittal images, from superior down to inferior. It can be seen that fiducial marker #5 was at the far superior location, and marker #1 was the most inferior. Three precontrast axial images are shown in Figure 2b , from superior to inferior, showing markers #3, #2, and #1, respectively. The corresponding color-coded contrast enhancement maps at 1 min after contrast injection are shown in Figure 2c . The reddish colors indicate higher enhancement, and dark blue colors indicate lower enhancement. The tumor enhancement was clearly demonstrated.
Reconstruction of MRI Along the DOS Scan Line
The fiducial markers as seen in the T1-weighted 3D dynamic images (DCE-MRI) were used as a visual guide in re-slicing the 3D dynamic MRI images along the DOS scan line using "ImageJ" software (1.30v, NIH). The original 32 slice DCE-MRI were first converted into volumetric image matrices with isotropic voxels to facilitate re-slicing in any plane by synthesizing slices between the original slices via weighted averaging. The locations of fiducial markers were manually outlined and then converted into the same sized volumetric matrix. Then the marker images were projected into three orthogonal projection planes in axial, coronal, and sagittal orientations, respectively. The plane which showed the highest number of markers was chosen to select the reslicing plane according the line through the center of markers (i.e., the DOS scan line). After the tangential plane through the DOS linescan was obtained, the transverse plane perpendicular to the DOS linescan at each marker location was then determined. This slice represented DOS volume at each individual DOS measurement site. Figure 3 shows the re-sliced plane along the fiducial markers from the Figure 2 case. In Figure 3a the re-sliced pre-contrast image is shown (a projection image from a 1.5 cm slab), and the five fiducials are marked as short segments on the breast surface. The corresponding enhancement map along the scan line is shown in Figure 3b . The depth of the tumor from the skin surface could be determined on this image. The orthogonal line at each marker position, representing the DOS volume covered between the DOS source-detector separation range, is also marked on Figures 3a and 3b . The transverse planes from tissues in a 1.5 cm slab covered under each marker position are shown in Figure 3c . The tumor region of interest (ROI) was manually drawn based on the enhancement maps shown in Figure 2c , and as such the tumor tissues covered in each DOS volume could be tracked. The percentage enhancement at 1 min after contrast injection (signal intensity enhancement at the 6 th frame normalized to the pre-contrast signal intensity) from the tumor tissues in each DOS volume was calculated.
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Results
Malignant tumors from six cases included in this study belong to three different morphological types, circumscribed mass (N=4), diffuse pattern (N=1), and the inflammatory septal pattern (N=1) (33, 34). Figures 3-8 show MR images with marker positions and TOI line scans from both tumor and contralateral normal breast for each case. The percent contrast enhancement from the tumor at 1 min after injection determined by MRI, and the peak THC and TOI values, as well as the TOI ratio between peak tumor value and the averaged normal value from the contralateral breast tissues are summarized in Table II .
Well Circumscribed Mass
Patients #1-4 all had a single well-circumscribed mass with the diagnosis of invasive ductal carcinoma. For patient #1 (56-year-old) the re-sliced plane along the DOS scan line, the corresponding enhancement map, and the transverse plane at the location of each marker are shown in Figures 3a-3c . A hypo-intense area was found on pre-contrast images in the right breast (Fig. 3a) , which corresponded to a strongly enhancing mass with a well-defined boundary on the enhancement map (Fig. 3b ). The tumor measured 2.8 × 2.4 cm on the enhancement map, and the anterior margin of the tumor was 1.5 cm beneath the skin surface. The re-sliced transverse plan indicated that the tumor was covered under fiducial markers #4 and #5, not under #3 at the center of the DOS linescan. The position shift was possibly due to differ-ent body positioning (supine for DOS and prone for MRI). Due to this problem, only the peak values in both measurements are presented here. The cancer area within each slice was known, and the contrast enhancement percentage at 1 min after injection from the enhanced cancer tissues was 78%. DOS showed a clear TOI peak along the linescan of the tumor side and a relatively flat line from the normal tissues in the contralateral side (Fig. 3d) . The contrast in TOI between the tumor peak relative to the averaged TOI of normal tissue from the contralateral side was 3:1. Figure 4 shows the results from patient #2 (31-year-old) who also has a well circumscribed and very superficial (0.3 cm from the skin surface) mass in the lateral right breast. The tumor measured 3.0 × 2.4 cm on the enhancement map shown in Figure 4b and was covered under the middle fiducial marker #3. Again a nice sharp peak was found in the TOI line-scan data, which showed 6:1 contrast compared to the TOI of contralateral normal tissues. Figure 5 shows patient #3 (48-year-old) with a small mass (1.8 × 1.0 cm) in the subareolar region. This was another superficial tumor, 0.8 cm from the skin surface. Again a sharp TOI peak was found, which also demonstrated a high contrast (5:1) compared to the TOI of contralateral normal tissues.
Patient #4 (38-year-old) shows another case with a circumscribed mass (Fig. 6 ). The tumor was 3.6 × 2.8 cm and was the deepest among all six subjects (4.2 cm beneath the skin surface). Different from the previous three cases was that this cancer had a well-appreciated necrotic core as demonstrated on the original enhancement maps (4 mm thick) from two axial slices shown in Figure 6a . However, the necrotic core could not be seen on the re-sliced precontrast image or the enhancement map in Figure  6b , possibly due to the thick slab (1.5 cm). The TOI data along the scan line clearly demonstrated a dip within a broad peak, possibly reflecting the necrotic core. The contrast between the peak tumor TOI and the mean normal tissues in the contralateral breast was 3.2:1. Figure 7 shows the results from patient #5 (41-year-old), who had a ductal carcinoma presented with a diffusive pattern. Different from the previous four cases, the tumor could not be differentiated on the pre-contrast image (in Fig. 7a ), but after contrast injection an irregular shaped tumor 2.4 × 1.6 cm was clearly seen on the enhancement map (Fig. 7b) . The tumor did not have a clearly defined boundary, thus was classified as a diffuse pattern. The corresponding TOI line scan (Fig. 7c ) has increased TOI from positions 2-6 (TOI >2) with a peak at positions 4-5 (TOI ∼3.0). The relative TOI contrast to the contralateral normal tissue was the lowest among all six subjects (2.4 :1). Figure 8 shows the results for Patient #6 (51-year-old) diagnosed with inflammatory cancer. There was a large diffuse area of enhancement in an 8.3 × 5.7 cm region which involved almost all breast tissues other than fat. The enhancement map shown in Figure 8b demonstrates two main regions of high enhancements, in posterior and anterior regions. The corresponding TOI line-scan ( Fig. 8c) showed an increase in TOI in positions 3-14 with TOI peaks at position 7 and 10 (TOI of 5.6 and 4.3, respectively). The average TOI on the normal side was low 0.72 ± 0.2, which resulted in a high contrast between the tumor and the normal side (8:1).
Diffusive Tumor
Septal Pattern: Inflammatory Breast Cancer
Contrast Summary
Table III provides a summary of the DOS results for each patient in relation to the unaffected contra lateral normal breast tissue. The values used here are the maximum (or minimum in the case of lipids and S T O 2 ) values of the DOS linescan. The values in each column are the percent deviation of the DOS readings relative to the normal baseline. The normal baseline is defined as the unaffected contra lateral breast. The average and standard deviations for all the values are summarized at the bottom of each column. The TOI, as described earlier, is a contrast function derived from an evaluation of DOS measurements in a population of 58 malignant breast tumors.
In Table III , it is apparent that the majority of TOI contrast is due to the enormous contrast seen in water and hemoglobin (both oxy and deoxy). Lipids also display a high degree of contrast but is inverse in nature. On the average, the largest contributors to the TOI contrast originate from water and Hb-R. We have elected to use Hb-R as the best representation of Hemoglobin (both oxy and deoxy) because we have observed that Hb-R is the most sensitive parameter to the presence of a tumor (to be published). Of note, the S T O 2 itself has the lowest contrast of any of the parameters, and in some cases is quite small (3/6 have less than a 5% change).
Discussion
DOS-derived functional parameters qualitatively correlate with DCE-MRI image characteristics in all six subjects. Subjects 1-3 all have well circumscribed tumors that are clearly visible by enhancement with DCE-MRI as well as by a single TOI peak measured with DOS. Both the DCE MRI and DOS also displayed signals consistent with the less well defined and more heterogeneous tumors. For example, in patient #4 (Fig. 6) there is an intra-tumor dip in both TOI and MRI enhancement corresponding to the necrotic region in the center of the tumor. Another consistent heterogeneous trend is observed in patient #6 (Fig. 8) where there is a bimodal TOI peak in the DOS linescan that correlates well with the two separated enhanced regions in this septal type inflammatory cancer seen on DCE-MRI. Overall the general spatial characteristics of the tumors are well preserved by both modalities and correlate qualitatively with each other. We also observe that the TOI, which combines information from angiogenic (Hb-R) as well as stromal (Water/Lipid) tissue components, does a fairly good job of identifying regions of enhancement in the tissue. Such information could prove pivotal in differentiating between benign and malignant regions (17).
However there are also some discrepancies in the anatomical coregistration, namely in the size and location of the tumors. The width of the TOI peak is generally broader than the tumor size represented by MRI. Thus the tumor sizes do not match exactly between the two techniques. The diffuse nature of light transport and the coarse spatial sampling of the DOS measurement certainly contributed to this broadening.
The coregistration location also did not always line up in every case. The explanation for this discrepancy is likely due to the fact that DOS and MRI measurements were done serially using different breast geometries. The DOS measurement geometry is similar to a breast ultrasound (i.e., reflectance), where the subject lies in a supine position and the breast is allowed to lie in a natural dependent position, not in a fixed position. In the MRI measurement the subject is in a prone position and the breast is pendulant but confined in a breast coil immobilized with padding. The precise features of the tumor locations will vary between these two positions, especially for deep tumors (where it is far from the markers placed on the skin surface). Thus, the peak enhancement locations on MRI often do not coincide exactly with the peak location in DOS measurement. DOS-measured THC is thought to correspond to tumor blood volume. Since the delivery of MR contrast medium into the tumor is via blood perfusion, the early contrast enhancement is a good indicator of blood volume. The percentage of contrast enhancement at 1 min after injection of the contrast medium is reported in Table II . However, it can be seen that the data do not correlate with the peak THC values among these six patients. Again the discrepancy may be attributed to the previously mentioned geometrical factors related to tumor depth and the optical properties of background tissues. However, another issue is that because the DOS hand piece employs a reflection-style geometry, the entire tumor volume is not sampled. MRI enhancement is sampled over the entire tumor volume, whereas DOS samples only a fraction of the tumor volume. In order to make quantitative comparisons between THC and enhancement, coregistered volumes must be determined with better precision. Knowledge of the tumor depth from MRI may serve as a constraining factor to allow an accurate estimation of the tumor geometry (21, 25) . Correlations will also be improved with more sophisticated modeling analysis in conjunction with measurements made in a tomographic setting.
The use of the multi-modality markers helps the coregistration by providing reference points between DOS measure-ments and the MRI images. However, these markers by themselves cannot correct for the spatial variances induced by the differing breast geometries. We are currently exploring a 3D tracking system for the DOS probe that will allow us to better localize its position on the surface of the breast. Integrating with an appropriate deformation model, or performing DOS measurements in a simulated breast coil with the subject lying prone, should further minimize these spatial inconsistencies. Furthermore, using Monte Carlo maps of the sampled photon volume might improve the coregistration, as we have done in animal model tumors (22) and in human muscle (35) . This added step would allow for a direct comparison of the MRI and DOS sampled volumes.
MRI clearly has superior spatial resolution to DOS and this feature can be used to guide optical tomographic reconstruction schemes (25). On the other hand, DOS can also provide information that is not readily available to MRI, such as absolute hemoglobin concentrations and tumor hemoglobin oxygen saturation (22, 24) . These quantitative measurements may be very useful in optimizing therapeutic interventions since hypoxia and blood flow are known to impact the efficacy of both chemo-and radiation therapies (36) (37) (38) (39) .
Conclusions
In this pilot study we demonstrate the use of dynamic contrast enhanced MRI (DCE-MRI) combined with broadband Diffuse Optical Spectroscopy (DOS), to better define and characterize tumors found in human breast tissue. Initial results show that this bi-modality approach provides complementary information regarding tissue structure and function. A tissue optical index (TOI) that is a composite of both angiogenic and stromal features is found to correlate well with the spatial extent and intensity of MRI enhancement. Tumors of different morphological features had varying DOS properties that qualitatively matched DCE-MRI images. Because of differences in breast orientation between the two modalities, quantitative correlation may be difficult to achieve with the current analysis methods. Improvements must be made to model the inhomogeneous features of breast as well as to synchronize and coregister the measurement geometries.
